Login Register Cart 0
Generic placeholder image

Current Chinese Science

Editor-in-Chief

ISSN (Print): 2210-2981
ISSN (Online): 2210-2914

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article Section: Oncology

Current Diagnosis and Treatment for Hepatocellular Carcinoma with Macrovascular Tumor Thrombosis

Author(s): Zhen-Hua Chen, Jin-Kai Feng, Zong-Han Liu, Kang Wang and Shu-Qun Cheng*

Volume 3, Issue 6, 2023

Published on: 31 August, 2023

Page: [444 - 451] Pages: 8

DOI: 10.2174/2210298103666230726163734

Abstract

Macrovascular tumor thrombosis (MVTT) is common among patients with advanced hepatocellular carcinoma (HCC), and it contains two main types, portal vein tumor thrombus (PVTT) and hepatic vein tumor thrombus (HVTT). MVTT is a significant prognostic factor, and the prognosis of HCC with MVTT remains unsatisfactory. The classification of MVTT varies in different studies, and the management of HCC and MVTT differs among Eastern and Western countries. Over the past years, a multidisciplinary approach, including surgical resection, radiotherapy, and transcatheter arterial chemoembolization, especially the advent of new targeted drugs and immune checkpoint inhibitors, has brought considerable survival benefits for HCC patients with MVTT. Recently, multiple novel treatment strategies, such as neoadjuvant therapy or tumor downstaging based on radiotherapy, immunotherapy, and molecular-targeted therapy, have broadened the treatment landscape of MVTT. In this review, we conclude the consensus and progress regarding diagnosis and treatment for patients with HCC and MVTT.

Keywords: Hepatocellular carcinoma, macrovascular tumor thrombosis, diagnosis, multidisciplinary therapy, surgery, immunotherapy.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Zhang, Z M; Lai, E C The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus., Int. J. Surg.,, 2015, 20, 8-16.
[http://dx.doi.org/10.1016/j.ijsu.2015.05.009.] [PMID: 26026424]
[3]
Kokudo, T.; Hasegawa, K.; Matsuyama, Y.; Takayama, T.; Izumi, N.; Kadoya, M.; Kudo, M.; Kubo, S.; Sakamoto, M.; Nakashima, O.; Kumada, T.; Kokudo, N. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology, 2017, 66(2), 510-517.
[http://dx.doi.org/10.1002/hep.29225] [PMID: 28437844]
[4]
Lu, J.; Zhang, X.P.; Zhong, B.Y.; Lau, W.Y.; Madoff, D.C.; Davidson, J.C.; Qi, X.; Cheng, S.Q.; Teng, G.J. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: Comparing east and west. Lancet Gastroenterol. Hepatol., 2019, 4(9), 721-730.
[http://dx.doi.org/10.1016/S2468-1253(19)30178-5] [PMID: 31387735]
[5]
Bruix, J.; Reig, M.; Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150(4), 835-853.
[http://dx.doi.org/10.1053/j.gastro.2015.12.041] [PMID: 26795574]
[6]
Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in ad-vanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
[http://dx.doi.org/10.1056/NEJMoa0708857] [PMID: 18650514]
[7]
Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; Blanc, J.F.; Vogel, A.; Komov, D.; Evans, T.R.J.; Lopez, C.; Dutcus, C.; Guo, M.; Saito, K.; Kraljevic, S.; Tamai, T.; Ren, M.; Cheng, A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126), 1163-1173.
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1] [PMID: 29433850]
[8]
Kudo, M.; Kitano, M.; Sakurai, T.; Nishida, N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: The outstanding achievements of the liver cancer study group of japan. Dig. Dis., 2015, 33(6), 765-770.
[http://dx.doi.org/10.1159/000439101] [PMID: 26488173]
[9]
Korean Liver Cancer Association (KLCA);; National Cancer Center (NCC), Goyang, Korea. 2018 Korean liver cancer associationnational cancer center korea practice guidelines for the management of hepatocellular carcinoma. Korean J. Radiol., 2019, 20(7), 1042-1113.
[http://dx.doi.org/10.3348/kjr.2019.0140] [PMID: 31270974]
[10]
Shuqun, C.; Minshan, C.; Jianqiang, C. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget, 2017, 8(5), 8867-8876.
[http://dx.doi.org/10.18632/oncotarget.12817] [PMID: 27780939]
[11]
Cheng, S.; Chen, M.; Cai, J.; Sun, J.; Guo, R.; Bi, X.; Lau, W.Y.; Wu, M. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition). Liver Cancer, 2020, 9(1), 28-40.
[http://dx.doi.org/10.1159/000503685] [PMID: 32071907]
[12]
Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J-L.; Schirmacher, P.; Vilgrain, V. Management of hepatocellular carcinoma. J. Hepatol., 2018, 69(1), 182-236.
[http://dx.doi.org/10.1016/j.jhep.2018.03.019] [PMID: 29628281]
[13]
Shi, J.; Lai, E.C.H.; Li, N.; Guo, W.X.; Xue, J.; Lau, W.Y.; Wu, M.C.; Cheng, S.Q. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J. Hepatobiliary Pancreat. Sci., 2011, 18(1), 74-80.
[http://dx.doi.org/10.1007/s00534-010-0314-0] [PMID: 20686792]
[14]
Shi, J.; Lai, E.C.H.; Li, N.; Guo, W.X.; Xue, J.; Lau, W.Y.; Wu, M.C.; Cheng, S.Q. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann. Surg. Oncol., 2010, 17(8), 2073-2080.
[http://dx.doi.org/10.1245/s10434-010-0940-4] [PMID: 20131013]
[15]
Katagiri, S.; Yamamoto, M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg. Today, 2014, 44(2), 219-226.
[http://dx.doi.org/10.1007/s00595-013-0585-6] [PMID: 23591833]
[16]
Chen, Z.H.; Wang, K.; Zhang, X.P.; Feng, J.K.; Chai, Z.T.; Guo, W.X.; Shi, J.; Wu, M.C.; Lau, W.Y.; Cheng, S.Q. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg. Nutr., 2020, 9(6), 717-728.
[http://dx.doi.org/10.21037/hbsn.2019.10.07] [PMID: 33299827]
[17]
Kokudo, T.; Hasegawa, K.; Yamamoto, S.; Shindoh, J.; Takemura, N.; Aoki, T.; Sakamoto, Y.; Makuuchi, M.; Sugawara, Y.; Kokudo, N. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J. Hepatol., 2014, 61(3), 583-588.
[http://dx.doi.org/10.1016/j.jhep.2014.04.032] [PMID: 24798618]
[18]
Kokudo, T.; Hasegawa, K.; Matsuyama, Y.; Takayama, T.; Izumi, N.; Kadoya, M.; Kudo, M.; Ku, Y.; Sakamoto, M.; Nakashima, O.; Kaneko, S.; Kokudo, N. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J. Hepatol., 2016, 65(5), 938-943.
[http://dx.doi.org/10.1016/j.jhep.2016.05.044] [PMID: 27266618]
[19]
Wang, K.; Guo, W.X.; Chen, M.S.; Mao, Y.L.; Sun, B.C.; Shi, J.; Zhang, Y.J.; Meng, Y.; Yang, Y.F.; Cong, W.M.; Wu, M.C.; Lau, W.Y.; Cheng, S.Q. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus. Medicine, 2016, 95(11), e3015.
[http://dx.doi.org/10.1097/MD.0000000000003015] [PMID: 26986115]
[20]
Chen, Z H; Zhang, X P Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: A propensity score matching analysis., Hepatol Res., 2019, 49(4), 441-452.
[http://dx.doi.org/10.1111/hepr.13297.] [PMID: 30549370]
[21]
Zhang, X.P.; Gao, Y.Z.; Chen, Z.H.; Chen, M.S.; Li, L.Q.; Wen, T.F.; Xu, L.; Wang, K.; Chai, Z.T.; Guo, W.X.; Shi, J.; Xie, D.; Wu, M.C.; Yee Lau, W.; Cheng, S.Q. An eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study. Hepatology, 2019, 69(5), 2076-2090.
[http://dx.doi.org/10.1002/hep.30490] [PMID: 30586158]
[22]
Zhang, X-P.; Wang, K.; Gao, Y-Z.; Wei, X-B.; Lu, C-D.; Chai, ZT.; Zhen, Z-J.; Li, J.; Yang, D-H.; Zhou, D.; Fan, R-F.; Yan, M-L.; Xia, Y-J.; Liu, B.; Huang, Y-Q.; Zhang, F.; Hu, Y-R.; Zhong, CQ.; Lin, J-H.; Fang, K-P.; Cheng, Z-H.; Wu, M-C.; Lau, W.Y.; Cheng, S-Q. Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion. Br. J. Surg., 2020, 107(7), 865-877.
[http://dx.doi.org/10.1002/bjs.11524] [PMID: 32246475]
[23]
Park, J W; Chen, M; Colombo, M; Roberts, L R Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. Liver Int., 2015, 35(9), 2155-2166.
[http://dx.doi.org/10.1111/liv.12818.] [PMID: 25752327]
[24]
Silva, J.P.; Berger, N.G.; Tsai, S.; Christians, K.K.; Clarke, C.N.; Mogal, H.; White, S.; Rilling, W.; Gamblin, T.C. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis. HPB, 2017, 19(8), 659-666.
[http://dx.doi.org/10.1016/j.hpb.2017.04.016] [PMID: 28552299]
[25]
Liu, L.; Zhang, C.; Zhao, Y.; Qi, X.; Chen, H.; Bai, W.; He, C.; Guo, W.; Yin, Z.; Fan, D.; Han, G. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: Prognostic factors in a single-center study of 188 patients. BioMed. Res. Int., 2014, 2014, 1-8.
[http://dx.doi.org/10.1155/2014/194278] [PMID: 24800212]
[26]
Jang, J.W.; Bae, S.H.; Choi, J.Y.; Oh, H.J.; Kim, M.S.; Lee, S.Y.; Kim, C.W.; Chang, U.I.; Nam, S.W.; Cha, S.B.; Lee, Y.J.; Chun, H.J.; Choi, B.G.; Byun, J.Y.; Yoon, S.K. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother. Pharmacol., 2006, 59(1), 9-15.
[http://dx.doi.org/10.1007/s00280-006-0239-0] [PMID: 16614848]
[27]
Luo, J.; Guo, R.P.; Lai, E.C.H.; Zhang, Y.J.; Lau, W.Y.; Chen, M.S.; Shi, M. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: A prospective comparative study. Ann. Surg. Oncol., 2011, 18(2), 413-420.
[http://dx.doi.org/10.1245/s10434-010-1321-8] [PMID: 20839057]
[28]
Kim, H.C.; Lee, J.H.; Chung, J.W.; Kang, B.; Yoon, J.H.; Kim, Y.J.; Lee, H.S.; Jae, H.J.; Park, J.H. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J. Vasc. Interv. Radiol., 2013, 24(2), 274-283.
[http://dx.doi.org/10.1016/j.jvir.2012.11.002] [PMID: 23369561]
[29]
Chern, M.C.; Chuang, V.P.; Cheng, T.; Lin, Z.H.; Lin, Y.M. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc. Intervent. Radiol., 2008, 31(4), 735-744.
[http://dx.doi.org/10.1007/s00270-008-9342-4] [PMID: 18427894]
[30]
Guo, R-P.; Wei, W.; Wang, J.; Xu, L.; Jian, P.; Xiao, C.; Zhong, X.; Shi, M.; Zhang, Y. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. OncoTargets Ther., 2016, 9, 4239-4246.
[http://dx.doi.org/10.2147/OTT.S106659] [PMID: 27471398]
[31]
Sun, J.; Guo, R.; Bi, X.; Wu, M.; Tang, Z.; Lau, W.Y.; Zheng, S.; Wang, X.; Yu, J.; Chen, X.; Fan, J.; Dong, J.; Chen, Y.; Cui, Y.; Dai, C.; Fang, C.; Feng, S.; Ji, Z.; Jia, W.; Jia, N.; Li, G.; Li, J.; Li, Q.; Li, J.; Liang, T.; Liu, L.; Lu, S.; Lv, Y.; Mao, Y.; Meng, Y.; Meng, Z.; Shen, F.; Shi, J.; Sun, H.; Tao, K.; Teng, G.; Wan, X.; Wen, T.; Wu, L.; Xia, J.; Ying, M.; Zhai, J.; Zhang, L.; Zhang, X.; Zhang, Z.; Zhao, H.; Zheng, D.; Zhi, X.; Zhou, J.; Zhou, C.; Zhou, J.; Zeng, Z.; Zhu, K.; Chen, M.; Cai, J.; Cheng, S. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition). Liver Cancer, 2022, 11(4), 315-328.
[http://dx.doi.org/10.1159/000523997] [PMID: 35978596]
[32]
Yoon, S.M.; Ryoo, B.Y.; Lee, S.J.; Kim, J.H.; Shin, J.H.; An, J.H.; Lee, H.C.; Lim, Y.S. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion. JAMA Oncol., 2018, 4(5), 661-669.
[http://dx.doi.org/10.1001/jamaoncol.2017.5847] [PMID: 29543938]
[33]
Onishi, H.; Nouso, K.; Nakamura, S.; Katsui, K.; Wada, N.; Morimoto, Y.; Miyahara, K.; Takeuchi, Y.; Kuwaki, K.; Yasunaka, T.; Miyake, Y.; Shiraha, H.; Takaki, A.; Kobayashi, Y.; Sakaguchi, K.; Kanazawa, S.; Yamamoto, K. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol. Int., 2015, 9(1), 105-112.
[http://dx.doi.org/10.1007/s12072-014-9592-y] [PMID: 25788384]
[34]
Chen, Z.H.; Zhang, X.P.; Feng, S.; Feng, J.K.; Chai, Z.T.; Guo, W.X.; Shi, J.; Lau, W.Y.; Meng, Y.; Cheng, S.Q. Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: A propensity score matching analysis. Hepatobiliary Surg. Nutr., 2021, 10(5), 646-660.
[http://dx.doi.org/10.21037/hbsn.2020.03.20] [PMID: 34760968]
[35]
Luo, J.J.; Zhang, Z.H.; Liu, Q.X.; Zhang, W.; Wang, J.H.; Yan, Z.P. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol. Int., 2016, 10(1), 185-195.
[http://dx.doi.org/10.1007/s12072-015-9663-8] [PMID: 26341514]
[36]
Huang, M.; Lin, Q.; Wang, H.; Chen, J.; Bai, M.; Wang, L.; Zhu, K.; Jiang, Z.; Guan, S.; Li, Z.; Qian, J.; Li, M.; Pang, P.; Shan, H. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: A retrospective matched cohort study. Eur. Radiol., 2016, 26(10), 3428-3436.
[http://dx.doi.org/10.1007/s00330-015-4198-x] [PMID: 26792430]
[37]
Sun, H.; Zhang, M.; Liu, R.; Liu, Y.; Hou, Y.; Wu, C. Endovascular implantation of 125 I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol., 2018, 14(12), 1165-1176.
[http://dx.doi.org/10.2217/fon-2017-0354] [PMID: 29334777]
[38]
Lau, W.Y.; Sangro, B.; Chen, P.J.; Cheng, S.Q.; Chow, P.; Lee, R.C.; Leung, T.; Han, K.H.; Poon, R.T.P. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90. Oncology, 2013, 84(5), 311-318.
[http://dx.doi.org/10.1159/000348325] [PMID: 23615394]
[39]
Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol., 2009, 10(1), 25-34.
[http://dx.doi.org/10.1016/S1470-2045(08)70285-7] [PMID: 19095497]
[40]
Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; Gerolami, R.; Masi, G.; Ross, P.J.; Song, T.; Bronowicki, J.P.; Ollivier-Hourmand, I.; Kudo, M.; Cheng, A.L.; Llovet, J.M.; Finn, R.S.; LeBerre, M.A.; Baumhauer, A.; Meinhardt, G.; Han, G. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 389(10064), 56-66.
[http://dx.doi.org/10.1016/S0140-6736(16)32453-9] [PMID: 27932229]
[41]
Qin, S.; Li, Q.; Gu, S.; Chen, X.; Lin, L.; Wang, Z.; Xu, A.; Chen, X.; Zhou, C.; Ren, Z.; Yang, L.; Xu, L.; Bai, Y.; Chen, L.; Li, J.; Pan, H.; Cao, B.; Fang, W.; Wu, W.; Wang, G.; Cheng, Y.; Yu, Z.; Zhu, X.; Jiang, D.; Lu, Y.; Wang, H.; Xu, J.; Bai, L.; Liu, Y.; Lin, H.; Wu, C.; Zhang, Y.; Yan, P.; Jin, C.; Zou, J. Apatinib as secondline or later therapy in patients with advanced hepatocellular carcinoma (AHELP): A multicentre, double-blind, randomised, placebocontrolled, phase 3 trial. Lancet Gastroenterol. Hepatol., 2021, 6(7), 559-568.
[http://dx.doi.org/10.1016/S2468-1253(21)00109-6] [PMID: 33971141]
[42]
Abou-Alfa, G.K.; Meyer, T.; Cheng, A.L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.W.; Blanc, J.F.; Bolondi, L.; Klümpen, H.J.; Chan, S.L.; Zagonel, V.; Pressiani, T.; Ryu, M.H.; Venook, A.P.; Hessel, C.; Borgman-Hagey, A.E.; Schwab, G.; Kelley, R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med., 2018, 379(1), 54-63.
[http://dx.doi.org/10.1056/NEJMoa1717002] [PMID: 29972759]
[43]
Zhu, A.X.; Kang, Y.K.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; Lim, H.Y.; Rau, K.M.; Motomura, K.; Ohno, I.; Merle, P.; Daniele, B.; Shin, D.B.; Gerken, G.; Borg, C.; Hiriart, J.B.; Okusaka, T.; Morimoto, M.; Hsu, Y.; Abada, P.B.; Kudo, M. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2019, 20(2), 282-296.
[http://dx.doi.org/10.1016/S1470-2045(18)30937-9] [PMID: 30665869]
[44]
Ding, X.; Sun, W.; Li, W.; Shen, Y.; Guo, X.; Teng, Y.; Liu, X.; Zheng, L.; Li, W.; Chen, J. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer, 2021, 127(20), 3782-3793.
[http://dx.doi.org/10.1002/cncr.33677] [PMID: 34237154]
[45]
Zhang, X.; Wang, K.; Wang, M.; Yang, G.; Ye, X.; Wu, M.; Cheng, S. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis. Oncotarget, 2017, 8(17), 29416-29427.
[http://dx.doi.org/10.18632/oncotarget.15075] [PMID: 28177886]
[46]
Zhang, Z.; Li, C.; Liao, W.; Huang, Y.; Wang, Z. A combination of sorafenib, an immune checkpoint inhibitor, TACE and stereotactic body radiation therapy versus sorafenib and TACE in advanced hepatocellular carcinoma accompanied by portal vein tumor thrombus. Cancers, 2022, 14(15), 3619.
[http://dx.doi.org/10.3390/cancers14153619] [PMID: 35892878]
[47]
Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; Li, D.; Verret, W.; Xu, D.Z.; Hernandez, S.; Liu, J.; Huang, C.; Mulla, S.; Wang, Y.; Lim, H.Y.; Zhu, A.X.; Cheng, A.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med., 2020, 382(20), 1894-1905.
[http://dx.doi.org/10.1056/NEJMoa1915745] [PMID: 32402160]
[48]
Ren, Z.; Xu, J.; Bai, Y.; Xu, A.; Cang, S.; Du, C.; Li, Q.; Lu, Y.; Chen, Y.; Guo, Y.; Chen, Z.; Liu, B.; Jia, W.; Wu, J.; Wang, J.; Shao, G.; Zhang, B.; Shan, Y.; Meng, Z.; Wu, J.; Gu, S.; Yang, W.; Liu, C.; Shi, X.; Gao, Z.; Yin, T.; Cui, J.; Huang, M.; Xing, B.; Mao, Y.; Teng, G.; Qin, Y.; Wang, J.; Xia, F.; Yin, G.; Yang, Y.; Chen, M.; Wang, Y.; Zhou, H.; Fan, J. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study. Lancet Oncol., 2021, 22(7), 977-990.
[http://dx.doi.org/10.1016/S1470-2045(21)00252-7] [PMID: 34143971]
[49]
Xu, J.; Shen, J.; Gu, S.; Zhang, Y.; Wu, L.; Wu, J.; Shao, G.; Zhang, Y.; Xu, L.; Yin, T.; Liu, J.; Ren, Z.; Xiong, J.; Mao, X.; Zhang, L.; Yang, J.; Li, L.; Chen, X.; Wang, Z.; Gu, K.; Chen, X.; Pan, Z.; Ma, K.; Zhou, X.; Yu, Z.; Li, E.; Yin, G.; Zhang, X.; Wang, S.; Wang, Q. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial. Clin. Cancer Res., 2021, 27(4), 1003-1011.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-2571] [PMID: 33087333]
[50]
Finn, R.S.; Ikeda, M.; Zhu, A.X.; Sung, M.W.; Baron, A.D.; Kudo, M.; Okusaka, T.; Kobayashi, M.; Kumada, H.; Kaneko, S.; Pracht, M.; Mamontov, K.; Meyer, T.; Kubota, T.; Dutcus, C.E.; Saito, K.; Siegel, A.B.; Dubrovsky, L.; Mody, K.; Llovet, J.M. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectablehepatocellular carcinoma. J. Clin. Oncol., 2020, 38(26), 2960-2970.
[http://dx.doi.org/10.1200/JCO.20.00808] [PMID: 32716739]
[51]
Kelley, R.K.; Sangro, B.; Harris, W.; Ikeda, M.; Okusaka, T.; Kang, Y.K.; Qin, S.; Tai, D.W.M.; Lim, H.Y.; Yau, T.; Yong, W.P.; Cheng, A.L.; Gasbarrini, A.; Damian, S.; Bruix, J.; Borad, M.; Bendell, J.; Kim, T.Y.; Standifer, N.; He, P.; Makowsky, M.; Negro, A.; Kudo, M.; Abou-Alfa, G.K. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study. J. Clin. Oncol., 2021, 39(27), 2991-3001.
[http://dx.doi.org/10.1200/JCO.20.03555] [PMID: 34292792]
[52]
Tella, S.H.; Kommalapati, A.; Mahipal, A.; Jin, Z. First-line targeted therapy for hepatocellular carcinoma: Role of atezolizumab/bevacizumab combination. Biomedicines, 2022, 10(6), 1304.
[http://dx.doi.org/10.3390/biomedicines10061304] [PMID: 35740326]
[53]
Tsai, H.M.; Han, M.Z.; Lin, Y.J.; Chang, T.T.; Chen, C.Y.; Cheng, P.N.; Chuang, C.H.; Wu, I.C.; Chen, P.J.; Kang, J.W.; Chiu, Y.C.; Chiu, H.C.; Chien, S.C.; Kuo, H.Y. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunol. Immunother., 2021, 70(7), 1929-1937.
[http://dx.doi.org/10.1007/s00262-020-02845-9] [PMID: 33409737]
[54]
Wei, X.; Jiang, Y.; Zhang, X.; Feng, S.; Zhou, B.; Ye, X.; Xing, H.; Xu, Y.; Shi, J.; Guo, W.; Zhou, D.; Zhang, H.; Sun, H.; Huang, C.; Lu, C.; Zheng, Y.; Meng, Y.; Huang, B.; Cong, W.; Lau, W.Y.; Cheng, S. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: A randomized, open-label, multicenter controlled study. J. Clin. Oncol., 2019, 37(24), 2141-2151.
[http://dx.doi.org/10.1200/JCO.18.02184] [PMID: 31283409]
[55]
Serenari, M.; Cappelli, A.; Cucchetti, A.; Mosconi, C.; Strigari, L.; Monari, F.; Ravaioli, M.; Rizzini, E.L.; Fanti, S.; Golfieri, R.; Cescon, M. Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: A pilot study. Liver Transpl., 2021, 27(12), 1758-1766.
[http://dx.doi.org/10.1002/lt.26257] [PMID: 34355489]
[56]
Martelletti, C.; Ricotti, A.; Gesualdo, M.; Carucci, P.; Gaia, S.; Rolle, E.; Burlone, M.E.; Okolicsanyi, S.; Mattalia, A.; Pirisi, M.; Berchialla, P.; Tabone, M. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and B ayesian analysis. J. Dig. Dis., 2021, 22(8), 496-502.
[http://dx.doi.org/10.1111/1751-2980.13030] [PMID: 34189839]
[57]
Hamaoka, M; Kobayashi, T; Kuroda, S Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study., Int. J. Surg., 2017, 44, 223-228.
[http://dx.doi.org/10.1016/j.ijsu.2017.06.082.] [PMID: 28676383]
[58]
Chong, J.U.; Choi, G.H.; Han, D.H.; Kim, K.S.; Seong, J.; Han, K.H.; Choi, J.S. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. Ann. Surg. Oncol., 2018, 25(11), 3308-3315.
[http://dx.doi.org/10.1245/s10434-018-6653-9] [PMID: 30083834]
[59]
Huang, C.; Zhu, X.D.; Shen, Y.H.; Wu, D.; Ji, Y.; Ge, N.L.; Chen, L.L.; Tan, C.J.; Zhou, J.; Fan, J.; Sun, H.C. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A retrospective analysis. Biomark. Res., 2021, 9(1), 19.
[http://dx.doi.org/10.1186/s40364-021-00274-z] [PMID: 33743822]
[60]
Sun, J.; Yang, L.; shi, J.; Liu, C.; Zhang, X.; Chai, Z.; Lau, W.Y.; Meng, Y.; Cheng, S.Q. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial. Radiother. Oncol., 2019, 140, 20-25.
[http://dx.doi.org/10.1016/j.radonc.2019.05.006] [PMID: 31176205]
[61]
Liu, S.; Guo, L.; Li, H.; Zhang, B.; Sun, J.; Zhou, C.; Zhou, J.; Fan, J.; Ye, Q. Postoperative adjuvant trans-arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann. Surg. Oncol., 2018, 25(7), 2098-2104.
[http://dx.doi.org/10.1245/s10434-018-6438-1] [PMID: 29728879]
[62]
Zhang, X.P.; Liu, Y.C.; Chen, Z.H.; Sun, J.X.; Wang, K.; Chai, Z.T.; Shi, J.; Guo, W.X.; Wu, M.C.; Lau, W.Y.; Cheng, S.Q. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with hepatic vein invasion: A propensity score matching analysis. Ann. Surg. Oncol., 2019, 26(5), 1465-1473.
[http://dx.doi.org/10.1245/s10434-019-07223-z] [PMID: 30767178]

Rights & Permissions Print Cite
Article Metrics
7
2
© 2024 Bentham Science Publishers | Privacy Policy